Published in the journal ImmuniHorizons, it was explained that Patrys' deoxymab antibody, PAD-DX1, may have an application in treating inflammation as well as tumours. This would be both through the same mechanism, which also goes to support Patrys' earlier understandings of its compounds.
Patrys has previously shown, in mouse studies, that its compounds had an effect on brain cancers occurring from breast cancer. However, it was not certain whether this was from treating the brain cancer metastases or from stopping the spread from the breast tumours. It now appears that the compounds may prevent cancer metastases.
PAT-DX1 has been shown to reduce the formation of neutrophil extracellular traps (NETs) in neutrophil cells. The NETs are filled with strands of DNA, which is released from the neutrophils causing inflammation in the body. However, PAT-DX1 is known to bind to free DNA (which is what attracts it to cancer cells).
PAT-DX1 is known to gain access into cancer cell nuclei and disrupt the DNA damage repair process which destroys the cancer cells. NETs also rely on the DNA Damage Repair Process in being formed.
NETs have been shown by others to be involved in the development of cancer cells in the body, involved in cancer metastases, and also in inflammatory processes in the body.
Whilst the core focus for Patrys remains in oncology, the potentially valuable IP the company has filed in this field could lead to future out-licensing opportunities.
Bioshares recommendation: Speculative Buy Class B
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
